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Abstract GPIHBP1, a GPI-anchored protein of capillary endothelial cells, binds lipoprotein lipase
(LPL) within the subendothelial spaces and shuttles it to the capillary lumen. GPIHBP1-bound LPL is
essential for the margination of triglyceride-rich lipoproteins (TRLs) along capillaries, allowing the
lipolytic processing of TRLs to proceed. In peripheral tissues, the intravascular processing of TRLs
by the GPIHBP1–LPL complex is crucial for the generation of lipid nutrients for adjacent
parenchymal cells. GPIHBP1 is absent from the capillaries of the brain, which uses glucose for fuel;
however, GPIHBP1 is expressed in the capillaries of mouse and human gliomas. Importantly, the
GPIHBP1 in glioma capillaries captures locally produced LPL. We use NanoSIMS imaging to show
that TRLs marginate along glioma capillaries and that there is uptake of TRL-derived lipid nutrients
by surrounding glioma cells. Thus, GPIHBP1 expression in gliomas facilitates TRL processing and
provides a source of lipid nutrients for glioma cells.
DOI: https://doi.org/10.7554/eLife.47178.001
Introduction
GPIHBP1, a GPI-anchored protein of capillary endothelial cells, is required for lipoprotein lipase
(LPL)–mediated processing of triglyceride-rich lipoproteins (TRLs) (Beigneux et al., 2007).
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The principal function of GPIHBP1 is to capture LPL within the interstitial spaces, where it is secreted
by parenchymal cells, and then to shuttle this enzyme to the luminal surface of capillary endothelial
cells (Davies et al., 2010). GPIHBP1 is a long-lived protein (Young et al., 2011; Olafsen et al.,
2010) that moves bidirectionally across endothelial cells, with each trip to the abluminal plasma
membrane representing an opportunity to capture LPL and bring it to the capillary lumen
(Davies et al., 2012). When GPIHBP1 is absent or defective, LPL is stranded within the interstitial
spaces, where it remains bound to sulfated proteoglycans near the surface of cells (Young et al.,
2011; Davies et al., 2010; Allan et al., 2017a; Fong et al., 2016). The inability of LPL to reach the
capillary lumen in the absence of GPIHBP1 expression profoundly impairs TRL processing, resulting
in severe hypertriglyceridemia (chylomicronemia) (Beigneux et al., 2007; Davies et al., 2010;
Goulbourne et al., 2014).
GPIHBP1 is expressed in the capillary endothelial cells of peripheral tissues, with particularly high
levels of expression in heart and brown adipose tissue (Beigneux et al., 2007; Davies et al., 2010;
Fong et al., 2016). Most of the LPL within those tissues is bound to GPIHBP1 on capillaries
(Beigneux et al., 2007; Davies et al., 2010; Davies et al., 2012; Allan et al., 2017a; Fong et al.,
2016; Allan et al., 2017b; Allan et al., 2016), and the processing of TRLs in these tissues is robust,
generating fatty acid nutrients for nearby parenchymal cells (Fong et al., 2016; Jiang et al., 2014a;
He et al., 2018a). By contrast, GPIHBP1 is absent from capillaries of the brain (Young et al., 2011;
Davies et al., 2010; Olafsen et al., 2010), a tissue that depends on glucose for fuel
(Mergenthaler et al., 2013). When wild-type mice are injected intravenously with a GPIHBP1-spe-
cific antibody, the antibody rapidly binds to GPIHBP1-expressing capillaries in peripheral tissues and
disappears from the plasma (Davies et al., 2010; Olafsen et al., 2010). By contrast, there is no anti-
body binding to the capillaries of the brain (Davies et al., 2010; Olafsen et al., 2010).
For the lipolytic processing of TRLs to proceed, lipoproteins in the bloodstream must marginate
along the luminal surface of capillaries (Goulbourne et al., 2014). TRL margination along capillaries
depends on GPIHBP1, more specifically on GPIHBP1-bound LPL (Goulbourne et al., 2014). In
GPIHBP1-deficient mice, TRLs never stop along heart capillaries and instead simply ‘flow on by’ in
the bloodstream (Goulbourne et al., 2014). In wild-type mice, TRLs marginate along heart capillar-
ies, but TRL margination is absent along capillaries of the brain (Goulbourne et al., 2014).
Even though GPIHBP1 is not found in brain capillaries, there is ample evidence for LPL expression
within the brain (Ben-Zeev et al., 1990; Bessesen et al., 1993; Goldberg et al., 1989; Vilaro´ et al.,
1990; Yacoub et al., 1990; Eckel and Robbins, 1984). Several groups have found LPL in the rat
brain, specifically in neurons of the dentate gyrus and hippocampus, in pyramidal cells of the cortex,
and in Purkinje cells of the cerebellum (Ben-Zeev et al., 1990; Bessesen et al., 1993;
Goldberg et al., 1989; Vilaro´ et al., 1990; Eckel and Robbins, 1984). Using single-cell RNA
sequencing, Zhang et al. (2014) found Lpl transcripts in the resident macrophages of the brain
(microglia), with lower levels in astrocytes, neurons, and oligodendrocytes. Using the same
approach, Vanlandewijck et al. (2018) found LPL expression in brain smooth muscle cells and in
perivascular fibroblasts (at even higher levels than in microglial cells). Given the absence of GPIHBP1
expression in brain capillaries and the absence of TRL margination along brain capillaries, we have
proposed that the LPL in the brain probably has an extravascular function, presumably to hydrolyze
glycerolipids within the extracellular spaces (Young et al., 2011; Adeyo et al., 2012).
Despite the absence of GPIHBP1 expression in brain capillaries, we were curious about whether
GPIHBP1 might be expressed in the capillaries of gliomas. Glioma capillaries are morphologically
distinct from normal brain capillaries (Yuan et al., 1994; Hobbs et al., 1998; Monsky et al., 1999;
Bullitt et al., 2005), and the blood–brain barrier is often defective (Zhang et al., 1992). Electron
microscopy has suggested that glioblastoma capillaries resemble capillaries in peripheral tissues
(Vaz et al., 1996).
If GPIHBP1 were to be expressed in glioma capillaries, it could be relevant to glioma metabolism.
The GPIHBP1 might capture locally produced LPL, allowing for TRL margination and TRL processing,
and thereby providing a source of lipid nutrients for glioma cells. Interestingly, Dong et al. (2017)
documented LPL expression in gliomas. Also, several studies have raised the possibility that glioma
cells use fatty acids for fuel (Lin et al., 2017; Guo et al., 2011; Guo et al., 2009a; Guo et al.,
2009b; Guo et al., 2013) and that levels of free fatty acids are higher in gliomas than in normal brain
tissue (Guo et al., 2013; Gopal et al., 1963).
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In the current study, we sought to determine whether glioma capillaries express GPIHBP1 and, if
so, whether it binds LPL and facilitates TRL margination and the lipolytic processing of TRLs. In our
study, we took advantage of NanoSIMS imaging, a high-resolution mass spectrometry–based imag-
ing modality that makes it possible to visualize TRL margination and TRL processing in tissue sec-
tions (He et al., 2018a; Jiang et al., 2014a; Jiang et al., 2014b; He et al., 2017a; He et al., 2017b;
He et al., 2018b; He et al., 2018c). This imaging modality allowed us to visualize TRL margination
in glioma capillaries as well as the entry of TRL-derived nutrients into tumor cells.
Results
GPIHBP1 is expressed in the endothelial cells of human gliomas
We sectioned 20 human gliomas (Table 1) and screened them for GPIHBP1 expression by confocal
microscopy with three GPIHBP1-specific monoclonal antibodies (mAbs) — RF4, which binds to resi-
dues 27–44 downstream from GPIHBP1’s acidic domain (Kristensen et al., 2018); and RE3 and RG3,
which both bind to GPIHBP1’s LU (Ly6/uPAR) domain (Hu et al., 2017). GPIHBP1 in capillary endo-
thelial cells was detected in 14 of 20 gliomas (Table 1) and colocalized with von Willebrand factor,
an endothelial cell marker (Figure 1). GPIHBP1 expression in glioma capillaries did not appear to
correlate with glioma grade, 1p/19q co-deletions, or IDH1 mutations (Table 1). GPIHBP1 was not
detectable in the capillaries of human brain specimens (Figure 1). The GPIHBP1 in glioma capillaries
could be detected with all three GPIHBP1-specific mAbs (Figure 2A). To be confident in the
Table 1. Human glioma tumor specimens.
Expression of GPIHBP1 was assessed by immunohistochemistry with mAbs against human GPIHBP1 (RF4, RE3, RG3). Those conducting
the studies were blinded to diagnoses. This table details the tumor diagnosis, location, 1p/19q co-deletion, and IDH1 mutation status,
as well as the presence of GPIHBP1.
Sample
ID Tissue diagnosis Location
1p/19q co-
deletion
IDH1
mutation GPIHBP1
1 Glioblastoma (GBM) Right frontal, parietal No Negative Yes
2 GBM Left temporal No Negative Yes
3 GBM Right occipital No Negative Yes
4 GBM Left frontal No Negative Yes
5 Oligodendroglioma Grade II Left anterior temporal, left posterior
temporal
Yes Negative Yes
6 Oligoastrocytoma Grade III Right temporal No Negative Yes
7 GBM + oligodendroglial component Left frontal Yes Negative Yes
8 GBM + extensive oligodendroglial
component
Right frontal No Negative Yes
9 Oligodendroglioma Grade III Left frontal Yes +R132H Yes
10 Oligodendroglioma Grade III Left frontal Yes +R132H Yes
11 Oligoastrocytoma Right parietal No Negative Yes
12 Oligodendroglioma Grade III Right parietal Yes +R132H Yes
13 Oligodendroglioma Grade III Right parietal Yes Negative Yes
14 Oligoastrocytoma Grade III Left temporal No +R132H Yes
15 Oligoastrocytoma Grade III Right temporal No +R132G No
16 Oligoastrocytoma Grade III Right frontal No +R132H No
17 Oligodendroglioma Grade III Left frontal Yes Negative No
18 Oligodendroglioma Grade III Left frontal Yes +R132H No
19 Oligodendroglioma Grade III Left temporal Yes Negative No
20 Oligodendroglioma Grade III Right temporal Yes +R132H No
DOI: https://doi.org/10.7554/eLife.47178.005
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Figure 1. GPIHBP1 expression in the endothelial cells of several human gliomas. Immunohistochemical studies on surgically resected gliomas (Gliomas
1, 5, 9; Table 1) and non-diseased human frontal lobe (n = 3), revealing GPIHBP1 expression in capillaries of gliomas but not in frontal lobe specimens.
GPIHBP1 (detected with a combination of the mAbs RE3 and RF4, 10 mg/ml each [red]) colocalized with von Willebrand factor (vWF, a marker for
endothelial cells [green]), but not with glial fibrillary acidic protein (GFAP, a marker for astroglial cells [magenta]). DNA was stained with DAPI (blue).
Three sections of each tumor and normal brain were evaluated and representative images are shown. Scale bar, 50 mm.
DOI: https://doi.org/10.7554/eLife.47178.002
The following figure supplement is available for figure 1:
Figure supplement 1. Detecting GPIHBP1 in glioma capillaries with immunoperoxidase staining.
DOI: https://doi.org/10.7554/eLife.47178.003
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Figure 2. Detecting GPIHBP1 in capillaries of human glioma specimens with three different monoclonal antibodies (mAbs) against GPIHBP1. (A)
Confocal fluorescence microscopy studies on sections from glioma sample 1 (Table 1), demonstrating the detection of GPIHBP1 with three different
human GPIHBP1–specific monoclonal antibodies (mAbs). Tissue sections were fixed with 3% PFA and then stained with mAbs against human GPIHBP1
(RF4, RE3, or RG3, 10 mg/ml [red]), an antibody against von Willebrand factor (vWF[green]), and an antibody against glial fibrillary acidic protein (GFAP
Figure 2 continued on next page
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specificity of the antibodies, we performed studies in which recombinant human GPIHBP1 was
added to the GPIHBP1-specific mAbs before incubating the solution with the glioma sections. As
expected, the presence of recombinant GPIHBP1 eliminated binding of the GPIHBP1-specific mAbs
to glioma capillaries (Figure 2B). GPIHBP1 expression in glioma capillaries could also be detected
by immunoperoxidase staining (Figure 1—figure supplement 1).
GPIHBP1 is present in the capillary endothelial cells of mouse gliomas
To determine whether GPIHBP1 is expressed in a mouse model of glioblastoma, spheroids of synge-
neic C57BL/6 mouse CT-2A glioma cells (Seyfried et al., 1992; Oh et al., 2014), modified to
express a blue fluorescent protein (BFP) (Mathivet et al., 2017), were engrafted into the brains of
mice harboring an endothelial cell–specific Pdgfb-iCreERT2 transgene (Claxton et al., 2008) and a
ROSAmT/mG reporter allele (Muzumdar et al., 2007). ROSAmT/mG is a two-color fluorescent, mem-
brane-targeted Cre-dependent reporter allele. In the absence of Cre, all cells express a membrane-
localized tdTomato and fluoresce red. In the setting of Cre expression, cells express membrane-
localized EGFP (rather than tdTomato) and fluoresce green. Before tumor implantation, mice were
injected with tamoxifen to induce Pdgfb-driven Cre expression in endothelial cells; thus, the endo-
thelial cells of the mice expressed EGFP and fluoresced green. Mice harboring gliomas (after three
weeks of growth) were injected intravenously with an Alexa Fluor 647–conjugated antibody against
mouse GPIHBP1 (11A12) (Beigneux et al., 2009). Mice were perfused with PBS and then perfusion-
fixed with 2% PFA, and tumor sections were processed for confocal immunofluorescence micros-
copy. GPIHBP1 was detected in endothelial cells of the gliomas, colocalizing with EGFP (brain endo-
thelial cells), but GPIHBP1 was absent from capillaries in the adjacent normal brain (Figure 3,
Figure 3—figure supplement 1). Using transmission electron microscopy, we observed large and
irregularly shaped capillaries in gliomas, with numerous villus-like structures on the luminal surface of
endothelial cells (Figure 3—figure supplement 2), similar to findings reported for capillaries in
human gliomas (Vaz et al., 1996; Coomber et al., 1987; Weller et al., 1977).
The factors that regulate Gpihbp1 expression in the capillary endothelial cells of peripheral tis-
sues and gliomas are incompletely understood. However, a recent study found that Gpihbp1 tran-
script levels in rat aortic endothelial cells are upregulated by vascular endothelial growth factor
(VEGF) (Chiu et al., 2016), an angiogenic factor known to be expressed at high levels by glioma cells
(Plate et al., 1994; Pietsch et al., 1997; Christov et al., 1998). We found that Gpihbp1 expression
in the mouse brain endothelial cell line bEnd.3 is upregulated by recombinant VEGF (Figure 3—fig-
ure supplement 3).
GLUT1 is expressed in the capillaries of gliomas and normal brain
We used immunofluorescence microscopy to examine the expression of GPIHBP1 and GLUT1 (the
main glucose transporter in brain capillaries [Maher et al., 1994; Pardridge et al., 1990]) in mouse
gliomas and adjacent normal brain. GPIHBP1 expression was detected in gliomas but was absent in
the normal brain. The signal for GLUT1 was strong in the endothelial cells of the normal brain and
was easily detectable in the capillaries of gliomas (Figure 4, Figure 4—figure supplements 1–
2). Consistent findings were observed in single-cell RNA-seq studies on vascular cells of gliomas
(Ken Matsumoto, manuscript in preparation) and normal brain vascular cells (Vanlandewijck et al.,
2018; He et al., 2018d). Endothelial cells of gliomas (identifed by high von Willebrand factor [vWF]
expression) exhibit high expression of Gpihbp1 and somewhat lower levels of Glut1 expression (e.g.,
Endothelial cell cluster 5 in Figure 4—figure supplement 3). In normal brain, Glut1 was
highly expressed in endothelial cells, whereas Gpihbp1 expression was absent (Figure 4—figure
Figure 2 continued
[magenta]). All three GPIHBP1-specific mAbs detected GPIHBP1 in capillaries, colocalizing with von Willebrand factor. DNA was stained with DAPI
(blue). Scale bar, 50 mm. (B) Immunofluorescence confocal microscopy studies on human glioma sample 5, performed with mAbs RF4 and RE3 (10 mg/
ml) in the presence or absence of 50 mg of recombinant soluble human GPIHBP1 (hGPIHBP1). Adding recombinant hGPIHBP1 to the antibody
incubation abolished binding of the GPIHBP1-specific mAbs to GPIHBP1 on glioma capillaries. Images show GPIHBP1 (red), vWF (green), GFAP
(magenta), and DAPI (blue). Three sections of tumors were evaluated; representative images are shown. Scale bar, 50 mm.
DOI: https://doi.org/10.7554/eLife.47178.004
Hu et al. eLife 2019;8:e47178. DOI: https://doi.org/10.7554/eLife.47178 6 of 29
Research article Biochemistry and Chemical Biology Human Biology and Medicine
supplement 3). In Gpihbp1-deficient mice, GLUT1 expression was detectable in the capillaries of gli-
omas and normal brain (Figure 4—figure supplement 4).
Figure 3. GPIHBP1 is expressed by capillary endothelial cells in mouse gliomas. Confocal microscopy images of a
BFP-tagged CT-2A glioma implanted in a ROSAmT/mG::Pdgfb-iCreERT2 mouse, revealing the expression of
GPIHBP1 in capillary endothelial cells of the glioma but not those of normal brain. Tamoxifen was administered
prior to implantation of the glioma spheroid to activate membrane-targeted EGFP in endothelial cells (green).
After three weeks of glioma growth, mice were anesthetized and injected via the tail vein with an Alexa Fluor 647–
labeled antibody against mouse GPIHBP1 (11A12; red). The mice were then perfused with PBS and perfusion-fixed
with 2% PFA in PBS. Glioma and adjacent normal brain were harvested, and 200-mm-thick sections were imaged
by confocal microscopy. GPIHBP1 was present on endothelial cells of the glioma (blue) but was absent from
normal brain. High-magnification images of the boxed area are shown on the right. Three mice were evaluated;
representative images are shown. Scale bar, 50 mm.
DOI: https://doi.org/10.7554/eLife.47178.006
The following figure supplements are available for figure 3:
Figure supplement 1. GPIHBP1 is expressed in the capillaries of mouse glioma but not normal brain.
DOI: https://doi.org/10.7554/eLife.47178.007
Figure supplement 2. The morphology of glioma capillaries differs from that of capillaries in normal brain, as
revealed by transmission electron microscopy (TEM).
DOI: https://doi.org/10.7554/eLife.47178.008
Figure supplement 3. Vascular endothelial growth factor (VEGF) increases Gpihbp1 transcript levels in the mouse
brain microvascular endothelial cell line bEnd.3.
DOI: https://doi.org/10.7554/eLife.47178.009
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LPL is present on GPIHBP1-expressing capillaries of mouse gliomas
Most of the LPL in peripheral tissues (e.g., heart or brown adipose tissue) is bound to GPIHBP1 on
capillaries; consequently, LPL and GPIHBP1 colocalize in tissue sections (Young et al., 2011;
Davies et al., 2010; Davies et al., 2012; Allan et al., 2017a; Fong et al., 2016; Allan et al., 2017b;
Allan et al., 2016). We hypothesized that GPIHBP1-expressing endothelial cells of gliomas could
capture LPL. Several observations prompted us to consider this hypothesis. First, as noted earlier,
there is ample evidence for LPL expression in the brain (Ben-Zeev et al., 1990; Bessesen et al.,
1993; Goldberg et al., 1989; Vilaro´ et al., 1990; Yacoub et al., 1990; Zhang et al., 2014), and it
seemed reasonable that some of that LPL would reach high-affinity GPIHBP1-binding sites on endo-
thelial cells. Second, gliomas contain large numbers of macrophages (F4/80-expressing cells; Fig-
ure 5—figure supplement 1), and macrophages are known to express LPL (Mahoney et al., 1982).
Figure 4. Expression of GPIHBP1 and GLUT1 in the endothelial cells of mouse gliomas. Immunohistochemical
studies of a BFP-expressing CT-2A glioma (after three weeks of growth). Mice were injected via the tail vein with
an Alexa Fluor 647–labeled antibody against mouse GPIHBP1 (11A12; green), then perfused with PBS and
perfusion-fixed with 2% PFA. Glioma and adjacent normal brain tissue were harvested, then 200-mm thick sections
cut, fixed with 4% PFA, and stained with an antibody against GLUT1 (red). GPIHBP1 was present in the capillaries
of mouse gliomas (blue) but absent from the capillaries of the normal brain. High-magnification images in the
boxed region are shown below. Three mice were evaluated; representative images are shown. Scale bar, 50 mm.
DOI: https://doi.org/10.7554/eLife.47178.010
The following figure supplements are available for figure 4:
Figure supplement 1. GPIHBP1 and GLUT1 expression in glioma capillaries.
DOI: https://doi.org/10.7554/eLife.47178.011
Figure supplement 2. GPIHBP1 and GLUT1 in glioma capillaries.
DOI: https://doi.org/10.7554/eLife.47178.012
Figure supplement 3. Single-cell RNA-seq observations on normal mouse brain and mouse gliomas.
DOI: https://doi.org/10.7554/eLife.47178.013
Figure supplement 4. GLUT1 is detectable in the endothelial cells of gliomas and normal brain in wild-type
(Gpihbp1+/+) and Gpihbp1–/– mice.
DOI: https://doi.org/10.7554/eLife.47178.014
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We found that LPL could be detected in peritoneal macrophages from wild-type mice but not in
macrophages harvested from Lpl–/– mice carrying a skeletal muscle–specific human LPL transgene
(Lpl–/–MCK-hLPL) (Levak-Frank et al., 1995) (Figure 5—figure supplement 2). We also found that
LPL could be detected in some of the macrophages in mouse gliomas and in normal brain of wild-
type mice, but not in the brain of Lpl–/–MCK-hLPL mice (Figure 5—figure supplement 3). These
findings were consistent with single-cell RNA-seq data from glioma and normal brain, in which Lpl
transcripts were found in the macrophages of gliomas and microglia of normal brain (Figure 4—fig-
ure supplement 3). Lpl transcripts are not present in capillary endothelial cells. Third, the most
highly upregulated fatty acid metabolism gene in human gliomas, compared to normal brain tissue,
is LPL (Figure 5—figure supplement 4). The second most perturbed gene in gliomas is CD36, which
encodes a putative fatty acid transporter (Figure 5—figure supplement 4).
To determine whether LPL is bound to GPIHBP1-expressing capillaries of gliomas, we performed
immunohistochemical studies, taking advantage of an affinity-purified goat antibody against mouse
LPL (Page et al., 2006). These studies revealed colocalization of GPIHBP1 and LPL in glioma
capillaries (Figure 5, Figure 5—figure supplement 5). LPL was not present in the capillaries of the
normal brain or in the capillaries of gliomas from Gpihbp1–/– mice (Figure 5, Figure 5—figure sup-
plement 5). As expected, the binding of the goat LPL antibody to tissues of Lpl–/–MCK-hLPL mice
was low (Figure 5, Figure 5—figure supplement 5), whereas mouse LPL was easily detectable in
the heart capillaries of wild-type mice (colocalizing with GPIHBP1) (Figure 5—figure supplement 6).
Consistent with earlier publications (Ben-Zeev et al., 1990; Vilaro´ et al., 1990), we observed a
strong mouse LPL signal in the hippocampal neurons of wild-type mice but not of Lpl–/–MCK-hLPL
mice (Figure 5—figure supplement 7). Of note, LPL was undetectable in ‘secondary antibody–only’
experiments (i.e., when the incubation of the primary antibody with tissue sections was omitted) (Fig-
ure 5, Figure 5—figure supplement 5–7).
There is little reason to suspect that the expression of LPL influences the expression of GPIHBP1
in capillaries. The overexpression of human LPL in the skeletal muscle of Lpl–/–MCK-hLPL mice did
not alter levels of Gpihbp1 expression (Figure 5—figure supplement 8).
Margination of TRLs along glioma capillaries and uptake of TRL-derived
nutrients in glioma cells
Given the presence of GPIHBP1-bound LPL on glioma capillaries, we suspected that we might find
evidence of TRL margination and processing in gliomas. To test this idea, TRLs that were heavily
labeled with deuterated lipids ([2H]TRLs) (He et al., 2018a) were injected intravenously into mice
harboring CT-2A gliomas (after three weeks of glioma growth). After allowing the [2H]TRLs to circu-
late for either 1 min or 30 min, the mice were euthanized, extensively perfused with PBS, and perfu-
sion-fixed with carbodiimide/glutaraldehyde. Heart, brain, and glioma specimens were harvested
and processed for NanoSIMS imaging. 12C14N– or 1H– images were used to visualize tissue morphol-
ogy, and 2H/1H images were used to identify regions of 2H enrichment. The scale in the 2H/1H
images of brain and glioma specimens ranges from 0.00018 to 0.0003 (i.e., from levels slightly above
2H natural abundance to levels twice as high as 2H natural abundance). The scale in the heart 2H/1H
images ranges from 0.00018 to 0.0006. In mice euthanized 1 min after the [2H]TRLs injection, [2H]
TRL margination was visualized along the luminal surface of glioma and heart capillaries, but not
along the capillaries of normal brain (Figure 6A–B). After 1 min, deuterated lipids from the [2H]TRLs
had already entered glioma cells and were even found in cytosolic neutral lipid droplets of those
cells (Figure 6B). By contrast, 2H enrichment was virtually absent in normal brain. As expected
(He et al., 2018a), we observed substantial amounts of [2H]TRL-derived lipids in cardiomyocytes,
including in cytosolic lipid droplets. In gliomas harvested 30 min after the injection of [2H]TRLs, we
observed similar findings: TRL margination along capillaries of gliomas and heart and the uptake of
TRL-derived nutrients by glioma cells and cardiomyocytes (Figure 7). Again, [2H]TRL margination
was absent in capillaries of the normal brain at the 30-min time point, and we did not find 2H enrich-
ment in the parenchymal cells of the normal brain. We did, however, observe very low levels of 2H
enrichment in capillary endothelial cells of normal brain. Given the absence of TRL margination in
normal brain capillaries, we speculate that the very low amounts of 2H enrichment in brain capillary
endothelial cells may relate to [2H]TRL processing in the periphery, followed by the uptake of unes-
terified [2H]fatty acids by endothelial cells of the brain.
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Figure 5. Lipoprotein lipase (LPL) colocalizes with GPIHBP1 in glioma capillaries. Confocal immunofluorescence
microscopy studies on glioma and normal brain from wild-type and Gpihbp1–/– mice, along with the brain from an
Lpl–/– mouse carrying a skeletal muscle–specific human LPL transgene (MCK). Glioma and brain sections (10-mm-
thick) were fixed with 3% PFA and then stained with a mAb against mouse GPIHBP1 (11A12; green), a goat
antibody against mouse LPL (red), and a rabbit antibody against CD31 (white). LPL colocalizes with GPIHBP1 and
CD31 in the capillaries of gliomas; GPIHBP1 and LPL were absent from normal brain capillaries and from glioma
capillaries in Gpihbp1–/– mice. DNA was stained with DAPI (blue). No LPL was detected in the capillaries of Lpl-
Figure 5 continued on next page
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At both the 1-min and 30-min time points, we observed heterogeneity in 2H enrichment in glioma
cells, with occasional perivascular cells exhibiting striking 2H enrichment. We do not know the iden-
tity of the highly enriched perivascular cells (i.e., whether they are tumor cells, pericytes, or macro-
phages), nor do we understand why some cells within the glioma took up more [2H]TRL-derived
lipids than other cells.
As an experimental control, we injected a mouse with PBS alone rather than with [2H]TRLs. As
expected, there was no 2H enrichment in the tissues of that mouse (Figure 7—figure supplement
1).
We performed an additional study in which [2H]TRLs were injected intravenously into a wild-type
mouse and a Gpihbp1–/– mouse. After 15 min, the hearts and brains from these mice were harvested
and processed for NanoSIMS imaging. The 2H/1H ratio images revealed 2H enrichment in the heart
of the wild-type mouse but negligible 2H enrichment in the heart of the Gpihbp1–/– mouse (2H
enrichment in cardiomyocyte lipid droplets was only ~10% greater than natural abundance) (Fig-
ure 7—figure supplement 2). In hindsight, the negligible amounts of 2H enrichment in the heart of
the Gpihbp1–/– mouse was probably not surprising, given the very large pool of unlabeled triglycer-
ides in the bloodstream of Gpihbp1–/– mice (~50–100-fold higher than that in wild-type mice). At the
15-min time point, we were unable to detect 2H enrichment in the brain of either the wild-type
mouse or the Gpihbp1–/– mouse (Figure 7—figure supplement 2).
13C enrichment in gliomas following administration of 13C-labeled fatty
acids or 13C-labeled glucose by gastric gavage
In addition to studies of gliomas after an intravenous injection of [2H]TRLs, we performed NanoSIMS
imaging after administering 13C-labeled fatty acids or 13C-labeled glucose by gastric gavage (three
doses over 36 hr) (Figure 8). In the case of the 13C-labeled fatty acid experiments, it is likely that
most of the 13C-labeled lipids entered the bloodstream in chylomicrons. Once again, 12C14N–
images were useful for tissue morphology, and the 13C/12C ratio images were useful to identify
Figure 5 continued
deficient mice (MCK) or when the incubation with primary antibodies was omitted (Secondary Only). Staining of all
tissue sections was performed simultaneously, and all images were recorded with identical microscopy settings.
Three mice per genotype were evaluated; representative images are shown. Scale bar, 50 mm.
DOI: https://doi.org/10.7554/eLife.47178.015
The following figure supplements are available for figure 5:
Figure supplement 1. Large numbers of macrophages in mouse gliomas.
DOI: https://doi.org/10.7554/eLife.47178.016
Figure supplement 2. LPL is expressed in peritoneal macrophages from wild-type mice but not in macrophages
from Lpl–/–MCK-hLPL mice, as revealed by confocal immunofluorescence microscopy.
DOI: https://doi.org/10.7554/eLife.47178.017
Figure supplement 3. LPL is present in the macrophages of brain and gliomas, as revealed by confocal
immunofluorescence microscopy.
DOI: https://doi.org/10.7554/eLife.47178.018
Figure supplement 4. Heat map showing genes related to fatty acid metabolism that are upregulated in human
gliomas, compared to normal brain.
DOI: https://doi.org/10.7554/eLife.47178.019
Figure supplement 5. LPL colocalizes with GPIHBP1 in glioma capillaries, as revealed by confocal
immunofluorescence microscopy.
DOI: https://doi.org/10.7554/eLife.47178.020
Figure supplement 6. Mouse LPL is absent from tissues of an Lpl–/–MCK-hLPL mouse, as revealed by confocal
immunofluorescence microscopy.
DOI: https://doi.org/10.7554/eLife.47178.021
Figure supplement 7. LPL is present in the hippocampal neurons of wild-type mice, as revealed by confocal
immunofluorescence microscopy.
DOI: https://doi.org/10.7554/eLife.47178.022
Figure supplement 8. Mouse Gpihbp1, mouse Lpl, and human LPL transcript levels in 25-week-old wild-type and
Lpl–/–MCK-hLPL mice (MCK-hLPL).
DOI: https://doi.org/10.7554/eLife.47178.023
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Figure 6. NanoSIMS imaging reveals margination of [2H]TRLs along glioma capillaries and 2H enrichment in adjacent glioma cells. Four-month-old
C57BL/6 mice harboring CT-2A gliomas were fasted for 4 hr and then injected intravenously with 200 ml of [2H]TRLs. After 1 min, mice were
euthanized and perfusion-fixed with carbodiimide/glutaraldehyde. Tissue sections were processed for NanoSIMS imaging. (A) NanoSIMS images
showing margination of [2H]TRLs in glioma capillaries. 1H– images were created to visualize tissue morphology (upper panels). Composite 2H/1H (red)
Figure 6 continued on next page
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regions of 13C enrichment. The scale for the 13C/12C images ranges from 0.0115 to 0.0150 (from
slightly above 13C natural abundance to ~36% greater than natural abundance). After administering
13C-labeled fatty acids, 13C enrichment was observed in both glioma cells and in the capillary endo-
thelial cells of gliomas (Figure 8A). In some images, 13C-enriched cytosolic lipid droplets were visible
in glioma cells (Figure 8—figure supplement 1). 13C enrichment was virtually absent from normal
brain (Figure 8A). However, after adjusting the scale of the NanoSIMS images, a small amount of
13C enrichment was observed in capillary endothelial cells within the brain parenchyma (Figure 8—
figure supplement 2). As expected (He et al., 2018a), we observed substantial amounts of 13C
enrichment in cardiomyocytes (Figure 8A).
After administering [13C]glucose to mice, 13C enrichment was easily detectable in normal brain
but was even ~20% higher in gliomas (Figure 8B). We also observed 13C enrichment in cardiomyo-
cytes (Figure 8B). As expected, there was no 13C enrichment in the tissues of a mouse that was
administered PBS alone (Figure 8—figure supplement 3).
To determine whether an absence of GPIHBP1 expression would influence the growth of glioma
tumors, CT-2A glioma cells that had been stably transfected with a Gaussia luciferase reporter were
injected into the brains of wild-type and Gpihbp1–/– mice (n = 11/group). Tumor burden was
assessed in live animals by measuring luciferase activity in the blood (Mai et al., 2017; Tan-
nous, 2009). We observed no statistically significant differences in tumor growth, tumor size, or sur-
vival between wild-type and Gpihbp1–/– mice (Figure 8—figure supplement 4). This result was not
particularly surprising, given that gliomas have a robust capacity to utilize glucose-derived nutrients
(Figure 8B).
Discussion
We sought to determine whether GPIHBP1, despite its complete absence from the capillaries of the
brain, might nevertheless be expressed in the capillaries of gliomas. Using standard immunohis-
tochemistry procedures, we documented GPIHBP1 expression in capillary endothelial cells of human
gliomas and CT-2A-derived mouse gliomas. The expression of GPIHBP1 in glioma capillaries was
intriguing, but the crucial issue is whether LPL would be bound to the GPIHBP1. Additional immuno-
histochemistry studies on mouse gliomas revealed that LPL colocalizes with GPIHBP1 on glioma
capillaries, just as LPL colocalizes with GPIHBP1 in the capillaries of heart and brown adipose tissue
(Young et al., 2011; Davies et al., 2010; Davies et al., 2012; Allan et al., 2017a; Fong et al.,
2016; Allan et al., 2017b; Allan et al., 2016). The binding of LPL to GPIHBP1 was specific: the LPL-
specific goat antibody did not detect LPL in the capillaries of gliomas in Gpihbp1–/– mice, nor did it
detect any LPL in macrophages or hippocampal neurons of Lpl–/–MCK-hLPL mice. The colocalization
of GPIHBP1 and LPL in the capillaries of gliomas implied that we might find evidence for TRL mar-
gination and processing in these tumors. Indeed, we observed both [2H]TRL margination along gli-
oma capillaries and the entry of TRL-derived nutrients into glioma cells. Consistent with results of
earlier studies (Goulbourne et al., 2014; He et al., 2018a), TRL margination was absent from the
capillaries of normal brain, and we found no 2H enrichment in the brain parenchyma. We did, how-
ever, find very low levels of 2H enrichment in capillary endothelial cells of normal brain, perhaps as a
result of the uptake of fatty acids that are derived from TRL processing in peripheral tissues. We
observed consistent findings after administering [13C]fatty acids to mice by gastric gavage. In those
experiments, we observed strong 13C enrichment in gliomas but no 13C enrichment in the normal
brain (except for low levels of enrichment in capillary endothelial cells). After administering [13C]glu-
cose by gavage, 13C enrichment was observed in both gliomas and normal brain. It is important to
Figure 6 continued
and 1H– (blue) images reveal [2H]TRLs (white arrows) in glioma and heart capillaries (middle and lower panels). The lower panels are close-up images of
the regions outlined in the middle panels. 2H/1H ratio scales were set to show marginated TRLs. Scale bars, 4 mm. (B) NanoSIMS images showing
2H enrichment in glioma tissue. 12C14N– images were generated to visualize tissue morphology. 2H/1H ratio images reveal margination of [2H]TRLs
within the capillary lumen and 2H-enriched lipid droplets in gliomas and heart. There was no 2H enrichment in normal brain tissue. Scale bars, 4 mm.
The bar graph shows the average fold change ± SD in the 2H/1H ratio above natural abundance. The experiment was performed in two mice with a
minimum of seven images analyzed for each sample. Differences were assessed using a Student’s t-test with Welch’s correction.
DOI: https://doi.org/10.7554/eLife.47178.024
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Figure 7. NanoSIMS imaging showing 2H enrichment in gliomas 30 min after an intravenous injection of [2H]TRLs. Four-month-old C57BL/6 mice
harboring CT-2A gliomas were fasted for 4 hr and then injected intravenously with 200 ml of [2H]TRLs. After 30 min, mice were euthanized and
perfusion-fixed with carbodiimide/glutaraldehyde. Sections of glioma, brain, and heart were processed for NanoSIMS imaging. 12C14N– images were
created to visualize tissue morphology. 2H/1H ratio images reveal margination of [2H]TRLs along the capillary lumen (white arrows) and 2H enrichment in
glioma and heart, including in cytosolic lipid droplets. Images of normal brain revealed slight 2H enrichment in capillary endothelial cells. Scale bars, 4
mm. The bar graph shows the average fold change ± SD in the 2H/1H ratio above natural abundance. The experiment was performed in two mice, with
a minimum of seven images analyzed for each sample. Differences were assessed with a Student’s t-test with Welch’s correction.
Figure 7 continued on next page
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note that the [13C]fatty acids and the [13C]glucose were administered in three doses over 36 hr
before harvesting tissues for NanoSIMS analyses, allowing ample time for the labeled nutrients to be
utilized as fuel or to be converted into other nutrients (e.g., nonessential amino acids) (He et al.,
2018a; Sidossis et al., 1995; Schneider and Potter, 1957). Thus, after administering 13C-labeled
Figure 7 continued
DOI: https://doi.org/10.7554/eLife.47178.025
The following figure supplements are available for figure 7:
Figure supplement 1. Absence of 2H enrichment in glioma and brain of a mouse that had been given an injection of PBS alone.
DOI: https://doi.org/10.7554/eLife.47178.026
Figure supplement 2. Uptake of [2H]TRLs in heart and brain of Gpihbp1–/– mice.
DOI: https://doi.org/10.7554/eLife.47178.027
Figure 8. Tissue uptake of fatty acid and glucose-derived nutrients by mice harboring CT-2A gliomas. (A) NanoSIMS images showing 13C enrichment
in mouse tissues (brain, glioma, and heart) after oral administration of 13C-labeled mixed fatty acids to mice (three 80-mg doses administered 12 h
apart). 12C14N– images were generated to visualize tissue morphology; 13C/12C ratio images were used to visualize 13C enrichment in tissues. Scale
bars, 4 mm. (B) NanoSIMS images revealing 13C enrichment in tissues following oral administration of 13C-labeled glucose to mice (three 75-mg doses
given 12-h apart). 12C14N– images were generated to visualize tissue morphology; 13C/12C ratio images were generated to assess 13C enrichment in
tissues. Scale bars, 4 mm. The bar graphs show the average 13C/12C ratio ± SD multiplied by 10,000 for fatty acids (left) and glucose (right). Each
experiment was performed in two mice, with a minimum of seven images analyzed for each sample. Differences were assessed using a Student’s t-test
with Welch’s correction.
DOI: https://doi.org/10.7554/eLife.47178.028
The following figure supplements are available for figure 8:
Figure supplement 1. 13C-enriched lipid droplets in mouse glioma cells.
DOI: https://doi.org/10.7554/eLife.47178.029
Figure supplement 2. NanoSIMS imaging showing 13C enrichment in capillary endothelial cells of normal brain after administering 13C-labeled mixed
fatty acids by oral gavage (three doses of 80 mg administered 12 hr apart).
DOI: https://doi.org/10.7554/eLife.47178.030
Figure supplement 3. Absence of 13C enrichment in the glioma and brain of a mouse that had been given an injection of PBS alone.
DOI: https://doi.org/10.7554/eLife.47178.031
Figure supplement 4. Glioma studies in Gpihbp1+/+ and Gpihbp1–/– mice.
DOI: https://doi.org/10.7554/eLife.47178.032
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fatty acids or glucose to mice, the 13C in glioma cells was probably present in a variety of macromo-
lecules (e.g., glucose, lipids, proteins, and nucleic acids).
Documenting GPIHBP1 and LPL in glioma capillaries, combined with the discovery that TRL-
derived nutrients are taken up and utilized by glioma cells, opens a new chapter in glioma metabo-
lism research (Figure 9). Laboratories that are interested in glioma metabolism have typically
focused on the intrinsic metabolic properties of glioma cells and on how metabolic pathways in glio-
mas differ from those in normal brain (Lin et al., 2017; Guo et al., 2009a; Guo et al., 2009b;
Guo et al., 2013; Gopal et al., 1963; Strickland and Stoll, 2017; Agnihotri and Zadeh, 2016).
There have been suggestions, based on indirect observations of substrate utilization, that glioma
tumors are capable of utilizing fatty acids for fuel and for anabolic processes (Lin et al., 2017;
Guo et al., 2013; Mashimo et al., 2014; Ru et al., 2013; Zaidi et al., 2013). In those studies,
however, the assumption was that the fatty acids probably originated from the tumor cells by de
novo lipogenesis (Guo et al., 2011; Guo et al., 2009a; Guo et al., 2009b). No one, as far as we are
aware, had ever considered the possibility that gliomas might be capable of taking up and utilizing
nutrients from LPL-mediated intravascular processing of TRLs.
In an ultrastructural study of human gliomas, Vaz et al. (1996) commented that the morphology
of endothelial cells in gliomas resembles that of capillary endothelial cells in peripheral tissues, with
euchromatin-rich nuclei, occasional fenestrations, and numerous pinocytotic vesicles within the cyto-
plasm. The expression of GPIHBP1 (a hallmark of capillary endothelial cells in peripheral tissues) in
gliomas provides biochemical support for the notion that glioma capillaries resemble capillaries in
peripheral tissues (Vaz et al., 1996). Our electron microscopy studies confirmed that the morpho-
logical features of glioma capillaries and normal brain capillaries differ substantially.
We have relatively few insights into the molecular basis for GPIHBP1 expression in glioma capillar-
ies. One possibility is that the absence of a blood–brain barrier in glioma capillaries (Dubois et al.,
2014; Wolburg et al., 2012; Liebner et al., 2000; Sage and Wilson, 1994) permits the exposure of
endothelial cells to a paracrine factor that activates GPIHBP1 expression. Another possibility is that
GPIHBP1 expression is stimulated by the expression of VEGF that is produced by glioma cells
(Plate et al., 1994; Pietsch et al., 1997; Christov et al., 1998). In our studies, VEGF increased
GPIHBP1 expression in the mouse brain endothelial cell line bEnd.3.
Figure 9. Intravascular lipolysis as a source of lipid nutrients for gliomas. In normal brain (left panel), LPL is
produced by astrocytes, neurons, oligodendrocytes, and fibroblasts. Because GPIHBP1 is not expressed in
the capillaries of the brain parenchyma, we have proposed that LPL remains within the interstitial spaces of the
brain (i.e., that it has an extravascular function) (Adeyo et al., 2012; Young et al., 2011). In gliomas (right panel),
GPIHBP1 is expressed in capillary endothelial cells, allowing GPIHBP1 to capture locally produced LPL and
to shuttle it to the capillary lumen. Intravascular processing of triglyceride-rich lipoproteins in gliomas provides a
source of lipid nutrients for glioma cells. HSPGs, heparan sulfate proteoglycans.
DOI: https://doi.org/10.7554/eLife.47178.033
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In the past, other laboratories have reported that glioma tumor cells can transdifferentiate into
endothelial cells, thereby augmenting the vascular supply to tumors (Wang et al., 2010; Ricci-
Vitiani et al., 2010; Soda et al., 2011). For example, endothelial cells in human glioblastomas were
reported to harbor the same genetic alterations as the tumor cells, implying that at least some of
the glioblastoma endothelial cells originate from stem cells within the tumor (Wang et al., 2010;
Ricci-Vitiani et al., 2010). In another model (Soda et al., 2011), a Cre recombinase (Cre)-loxP–con-
trolled lentiviral vector encoding activated forms of H-Ras and Akt was injected into the hippocam-
pus of GFAP-Cre p53 mice, eliciting glioblastomas. In that model, the oncogenes were expressed in
the GFAP+ cells, and the resulting tumors expressed GFP, H-Ras, and Akt and the loss of p53. Some
GFP+ endothelial cells were observed in tumors, implying that these endothelial cells had originated
from tumor cells. Furthermore, implanting a tumor cell line (generated from tumors induced with the
same lentiviral vector) into the brain of immunocompromised mice was reported to yield tumors con-
taining GFP+ endothelial cells. In our current studies, we observed no evidence of the differentiation
of glioma cells into capillary endothelial cells. The glioma cell line that we used expressed blue fluo-
rescent protein (BFP), but we did not find BFP expression in the capillary endothelial cells of
gliomas.
Mass spectrometry–based analyses of homogenized tissue extracts from mouse gliomas and nor-
mal brain tissue, along with similar analyses of tumors from human patients, suggested differences in
acetate oxidation in gliomas vs. normal brain (Mashimo et al., 2014). Although these studies of tis-
sue extracts have been useful, they obviously cannot provide anatomical insights into metabolism.
We have argued that NanoSIMS imaging studies are particularly useful when the goal is to under-
stand metabolism at an anatomic level (cellular or subcellular) (He et al., 2018a). In the current stud-
ies, NanoSIMS imaging provided anatomic insights into glioma metabolism. For example, we
observed TRL margination along the capillaries of gliomas but not in the capillaries of adjacent nor-
mal brain tissue. We also showed that the transport of TRL-derived nutrients across glioma capillar-
ies and into glioma cells is rapid, occurring within 1 min, and that there is heterogeneity in nutrient
uptake by different cells within the tumor. We found no uptake of TRL-derived nutrients by normal
brain 1 or 15 min after the injection of [2H]TRLs and only very small amounts (confined to capillary
endothelial cells) after 30 min. In addition, following the administration of [13C]glucose, we found
more 13C enrichment in gliomas than in normal brain. As far as we are aware, our study is the first to
use NanoSIMS analyses to investigate cancer metabolism in vivo. As we look to the future, we have
little doubt that NanoSIMS imaging will be an important tool for understanding tumor metabolism,
making it possible to investigate metabolic heterogeneity in tumor cells along with the metabolic
properties of vascular cells, fibroblasts, and macrophages within the tumor. Nevertheless, it is impor-
tant to point out that NanoSIMS imaging is not high-throughput, at least with the current instru-
ments, and for that reason NanoSIMS imaging is best used (as in this study) to address discrete
anatomic issues in metabolism. Examining large numbers of tumors or large numbers of mice would
be difficult. Also, NanoSIMS imaging is very expensive.
Our studies have provided fresh insights into the uptake of lipid nutrients by gliomas, but many
issues remain to be investigated. For example, in the current studies, we found numerous macro-
phages within gliomas, but we did not address differences in nutrient uptake by macrophages and
glioma cells. In future studies, it should be possible to examine the uptake of TRL-derived nutrients
into tumor cells, macrophages, and other immune cells within gliomas (by identifying specific cell
types with 15N-labeled monoclonal antibodies or antibodies tagged with different lanthanide metals
[Waentig et al., 2012; Kanje et al., 2016; Angelo et al., 2014; Keren et al., 2018]). It would also
be desirable to determine whether the uptake of TRL-derived nutrients in gliomas correlates with
the levels of GPIHBP1 and LPL in glioma capillaries (as quantified with LPL- and GPIHBP1-specific
antibodies tagged with different lanthanide metals). Finally, it would be desirable to investigate
whether the presence of GPIHBP1 and LPL in glioma capillaries could be exploited for patient care.
For example, it is conceivable that fluorescently labeled GPIHBP1 antibodies or DiI-labeled TRLs
could guide the surgical resection of tumors. In addition, a localized injection of GPIHBP1-specific
monoclonal antibodies conjugated to chemotherapeutic agents into gliomas might be useful in tar-
geting tumor vasculature (Schrama et al., 2006). A localized injection of gold-conjugated GPIHBP1-
specific monoclonal antibodies could augment the efficacy of external beam radiotherapy
(Haume et al., 2016; Hainfeld et al., 2004; Hainfeld et al., 2008).
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Materials and methods
Key resources table
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Genetic
reagent (M. musculus)
Gpihbp1–/– Beigneux et al., 2007 RRID: MGI:3771172 Dr. Stephen
G Young (UCLA)
Genetic
reagent (M. musculus)
Lpl–/–MCK-hLPL Levak-Frank et al., 1995 RRID: MGI:3624988 Dr. Rudolph
Zechner (Graz University)
Genetic
reagent (M. musculus)
ROSAmT/mG
Pdgfb-iCreT2
Mathivet et al., 2017 Dr. Holger
Gerhardt (VIB KU-Leuven)
Cell line
(M. musculus)
CT-2A Seyfried et al., 1992 Dr. Thomas
Seyfried (Boston College)
Cell line
(M. musculus)
CT-2A–BFP PMID: 24658686 Dr. Holger Gerhardt (VIB KU-Leuven)
Cell line
(M. musculus)
bEnd.3 ATCC Catalog No. CRL-2299
RRID: CVCL_0170
Transfected construct
(lentiviral plasmid)
plenti-GLuc-IRES-EGFP Targeting Systems Catalog No. GL-GFP
Antibody Rat monoclonal
anti-mouse
GPIHBP1 (11A12)
Beigneux et al., 2009 Dr. Stephen
G Young (UCLA);
IHC (10 mg/ml)
Antibody Mouse monoclonal
anti-human
GPIHBP1 (RE3)
Hu et al., 2017 Dr. Stephen
G Young (UCLA);
IHC (10 mg/ml)
Antibody Mouse monoclonal
anti-human GPIHBP1 (RF4)
Hu et al., 2017 Dr. Stephen
G Young (UCLA);
IHC (10 mg/ml)
Antibody Mouse monoclonal
anti-human GPIHBP1 (RG3)
Hu et al., 2017 Dr. Stephen
G Young (UCLA);
IHC (10 mg/ml)
Antibody Rabbit polyclonal
anti-vWF
Dako Catalog No. A0082
RRID: AB_2315602
IHC (1:200)
Antibody Goat polyclonal
anti-GFAP
Abcam Catalog No. ab53554
RRID: AB_880202
IHC (1:200)
Antibody Rabbit polyclonal
anti-GLUT1
Millipore-Sigma Catalog No. 07–1401
RRID: AB_1587074
IHC (1:200)
Antibody Rabbit polyclonal
anti-CD31
Abcam Catalog No. ab28364
RRID: AB_726362
IHC (1:50)
Antibody Rat monoclonal
anti-F4/80
Abcam Catalog No. ab6640
RRID: AB_1140040
IHC (10 mg/ml)
Antibody Goat polyclonal
anti-mouse LPL
Page et al., 2006 Dr. Andre´ Bensadoun
(Cornell); IHC (12 mg/ml)
Antibody Alexa Fluor 488,
568, 647 secondaries
ThermoFisher Scientific IHC (1:500)
Commercial
assay or kit
ImmPRESS Excel
Staining Kit
Vector Laboratory Catalog No. MP-7602
Sequence-
based reagent
Mouse
Gpihbp1 primers
50-AGCAGGGACAGAGCACCTCT-30
and
50-AGACGAGCGTGATGCAGAAG-30
Sequence-
based reagent
Mouse Cd31 primers 50-AACCGTATCTCCAAAGCCAGT-30
and
50-CCAGACGACTGGAGGAGAACT-30
Sequence-
based reagent
Mouse Angpt2 primers 50-AACTCGCTCCTTCAGAAGCAGC-30
and
50-TTCCGCACAGTCTCTGAAGGTG-30
Continued on next page
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Continued
Reagent type
(species) or resource Designation Source or reference Identifiers
Additional
information
Sequence-
based reagent
Mouse Dusp5 primers 50-TCGCCTACAGACCAGCCTATGA-30
and
50-TGATGTGCAGGTTGGCGAGGAA-30
Sequence-
based reagent
Mouse Cxcr4 primers 50-GACTGGCATAGTCGGCAATGGA-30
and
50-CAAAGAGGAGGTCAGCCACTGA-30
Sequence-
based reagent
Mouse Lpl primers 50-AGGTGGACATCGGAGAACTG-30
and
50-TCCCTAGCACAGAAGATGACC-30
Sequence-
based reagent
Human LPL primers 50-TAGCTGGTCAGACTGGTGGA-30
and
50-TTCACAAATACCGCAGGTG-30
Recombinant
DNA reagent
ALO-D4 plasmid Gay et al., 2015 Dr. Arun Radhakrishnan
(UT Southwestern)
Chemical
compound, drug
N-(3-Dimethylaminopropyl)-
N0-ethylcarbodiimide
hydrochloride (carbodiimide)
Millipore-Sigma Catalog No. 03449
Chemical
compound, drug
Glutaraldehyde
25% solution
Electron
Microscopy Sciences
Catalog No. 16220
Chemical
compound, drug
Osmium
tetroxide 4% solution
Electron
Microscopy Sciences
Catalog No. 18459
Chemical
compound, drug
Paraformaldehyde
16% solution
Electron
Microscopy Sciences
Catalog No. 15170
Chemical
compound, drug
EMbed 812 Electron Microscopy Sciences Catalog No. 14120
Chemical
compound, drug
Sodium cacodylate
trihydrate
Electron
Microscopy Sciences
Catalog No. 12300
Chemical
compound, drug
Uranyl acetate SPI-Chem Catalog No. 02624AB
Chemical
compound, drug
DAPI ThermoFisher
Scientific
Catalog No. 1306 IHC (3 mg/ml)
Chemical
compound, drug
Mouse VEGF Millipore-Sigma Catalog No. V4512
Software,
algorithm
LIMMA Ritchie et al., 2015 RRID:
SCR_010943
Other D-GLUCOSE
(U-13C6, 99%)
Cambridge Isotope
Laboratories
Catalog No.
CLM-1396-PK
Other Mixed fatty
acids (U-D, 96–98%)
Cambridge Isotope
Laboratories
Catalog No.
DLM-8572-PK
Other Mixed fatty
acids (13C, 98%+)
Cambridge Isotope
Laboratories
Catalog No.
CLM-8455-PK
Immunohistochemical studies on human glioma specimens
Frozen surgical glioma specimens were obtained from the UCLA Department of Neurosurgery. Fro-
zen autopsy control brain samples (frontal lobe, occipital lobe, and cerebellum) were obtained from
the UCLA Section of Neuropathology. Samples were sectioned to 8 mm and placed on glass slides.
All samples were fixed with 3% paraformaldehyde (PFA) in PBS/Ca/Mg and permeabilized in 0.2%
Triton X-100 in PBS/Ca/Mg. Tissues were blocked with PBS/Ca/Mg containing 5% donkey serum
and 0.2% bovine serum albumin (BSA) and incubated overnight at 4˚C with one or more mouse
monoclonal antibodies (mAbs) against human GPIHBP1 (RF4, RE3, RG3; 10 mg/ml) (Hu et al., 2017),
a rabbit polyclonal antibody against von Willebrand factor (vWF) (Dako; 1:200), and a goat poly-
clonal antibody against human glial fibrillary acidic protein (GFAP) (Abcam; 1:500). In some experi-
ments, recombinant soluble human GPIHBP1 (50 mg) was added to the primary antibody incubation.
After washing the slides, 1-hr incubations were performed with an Alexa Fluor 647–conjugated
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donkey anti–mouse IgG (ThermoFisher Scientific; 1:500), an Alexa Fluor 488–conjugated donkey
anti–rabbit IgG (ThermoFisher Scientific; 1:500), and an Alexa Fluor 568–conjugated donkey anti–
goat IgG (ThermoFisher Scientific; 1:500). DNA was stained with 40,6-diamidino-2-phenylindole
(DAPI). Images were taken with an LSM700 confocal microscope with an Axiovert 200M stand and
processed with Zen 2010 software (Zeiss).
Immunoperoxidase staining was performed with the ImmPRESS Excel Staining Kit (Vector Labora-
tories). Endogenous peroxidase activity was quenched with BLOXALL Blocking Solution (Vector Lab-
oratories). After incubating sections in 10% normal horse serum, sections were incubated for 1 hr
with mAb RF4 (5 mg/ml), followed by a 15-min incubation with a goat anti-mouse IgG (10 mg/ml, Vec-
tor Laboratories). Slides were then incubated for 30 min with a horseradish peroxidase–conjugated
horse anti–goat IgG (ImmPRESS Excel Reagent, Vector Laboratories). After washing, the slides were
incubated with ImmPACT DAB EqV (Vector Laboratories) until a color change was evident (~30 s).
Finally, sections were counterstained with hematoxylin and mounted with Vectashield Mounting
Media (Vector Laboratories). Images were recorded with a Nikon Eclipse E600 microscope (Plan
Fluor 40/0.50 NA or 100/0.75 NA objectives) equipped with a DS-Fi2 camera (Nikon).
Genome dataset and gene-expression analyses
Cohorts for RNA-seq analysis were obtained from two databases: The Cancer Genome Atlas (TCGA)
for tumor samples and Genotype-Tissue Expression (GTEx) for normal brain samples. Samples from
TCGA (n = 157) and GTEx (n = 283) were processed with the TOIL pipeline as described
(Vivian et al., 2017). A differential expression analysis of fatty acid metabolism genes was carried
out with a linear model RNA-seq analysis software (LIMMA) (Ritchie et al., 2015). Genes were con-
sidered differentially expressed if the p-values were <0.05 and the log2 changes were >twofold. A
heatmap was generated with the software R (Kolde, 2015).
Animal procedures and glioma implantation
Mice on a C57BL/6 background expressing both the ROSAmT/mG Cre-reporter (Muzumdar et al.,
2007) and tamoxifen-inducible Pdgfb-iCreERT2 alleles (Claxton et al., 2008) were generated by
breeding. In those mice, the administration of tamoxifen induces Cre recombinase expression in
Pdgfb-positive cells. The recombination event results in the expression of EGFP in endothelial cells;
all other cells express tdTomato. For the glioma implantation studies, mice (8–12-weeks-old) were
injected intraperitoneally with tamoxifen (65 mg/g body weight, 4 injections in 2 weeks) before sur-
gery. Mice were anesthetized with ketamine/xylazine, and a craniotomy was performed by drilling a
5-mm hole between the lambdoid, sagittal, and coronal sutures. A blue fluorescent protein (BFP)-
tagged CT-2A glioblastoma spheroid (250-mm in diameter) (Seyfried et al., 1992; Oh et al., 2014)
was injected into the cortex and sealed by cementing a glass coverslip on the skull. The CT-2A cell
line was generated by Seyfried and coworkers through chemical induction with 20-methylcholan-
threne in the brain of C57BL/6 mice and has been characterized extensively (Seyfried et al., 1992).
In other experiments, CT-2A glioblastoma spheroids were implanted into the cortex of C57BL/6
wild-type mice and Gpihbp1–/– mice (Beigneux et al., 2007). Those procedures were performed as
described previously (Stanchi et al., 2019).
Immunohistochemical studies on mouse gliomas
Mice harboring BFP-expressing CT-2A gliomas (Seyfried et al., 1992; Oh et al., 2014) were anes-
thetized with ketamine/xylazine and then injected intravenously (via the tail vein) with 100 mg of an
Alexa Fluor 647–conjugated antibody against mouse GPIHBP1 (11A12) (Beigneux et al., 2009).
After 1 min, the mice were perfused through the heart with 15 ml of PBS, followed by 10 ml of 2%
PFA in PBS. Brain and glioma tissues were harvested and fixed overnight in 4% PFA. Tissue sections
(200-mm-thick) were prepared with a vibratome. For immunofluorescence microscopy studies, the
sections were fixed with 4% PFA in PBS and blocked and permeabilized in TNBT (0.1 M Tris, pH 7.4,
150 mM NaCl, 0.5% blocking reagent from Perkin Elmer, 0.5% Triton X-100) for 4 hr at room tem-
perature. Tissues were incubated with an antibody against GLUT1 (Millipore; 1:200) diluted in TNBT
buffer overnight at 4˚C, washed in TNT buffer (0.1 M Tris pH 7.4; 150 mM NaCl, 0.5% Triton X-100)
and incubated with an Alexa Fluor 488–conjugated donkey anti–rabbit IgG (ThermoFisher Scientific;
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1:200). Tissues were washed and mounted in fluorescent mounting medium (Dako). Images were
obtained with a Leica TCS SP8 confocal microscope.
For the analysis of tissues from mice that were not injected with anti-GPIHBP1 antibodies, tissues
were embedded in OCT medium, and 10-mm sections were cut with a cryostat. Sections were fixed
with 3% PFA in PBS/Ca/Mg, permeabilized with 0.2% Triton X-100 in PBS/Ca/Mg, and blocked with
PBS/Ca/Mg containing 5% donkey serum and 0.2% BSA. Tissue sections were incubated overnight
at 4˚C with a rabbit antibody against CD31 (Abcam; 1:50), a goat antibody against mouse LPL (12
mg/ml) (Page et al., 2006), an Alexa Fluor 488–conjugated antibody against F4/80, or an
Alexa Fluor 647–conjugated antibody against mouse GPIHBP1 (11A12, 10 mg/ml). After removing
non-bound antibodies and washing the sections, unlabeled primary antibodies were detected with
an Alexa Fluor 488–conjugated donkey anti–rabbit IgG (ThermoFisher Scientific; 1:500) or an
Alexa Fluor 568–conjugated donkey ant–goat IgG (ThermoFisher Scientific; 1:500). DNA was stained
with DAPI, and tissues were mounted with ProLong Gold mounting media (ThermoFisher Scientific).
Images were recorded on an LSM 800 confocal microscope (Zeiss).
Immunocytochemistry studies on mouse peritoneal macrophages
Macrophages were collected by peritoneal lavage of C57BL/6 wild-type and Lpl–/–MCK-hLPL mice.
Cells were centrifuged at 400  g for 5 min at 4˚C, washed with 5 ml of red blood cell lysing buffer
(Sigma) for 5 min, washed twice with cold PBS, and then plated onto FBS-coated Petri dishes. Cells
were cultured overnight in macrophage medium (Dulbecco Modified Eagle Medium with 10% FBS,
1% glutamine, and 1% sodium pyruvate). On the next day, macrophages were lifted with cold PBS
containing 5 mM EDTA for 30 min at 4˚C. Cells were then plated onto poly-D-lysine–coated glass
coverslips (75,000 cells/coverslip) and incubated overnight in macrophage media. On the following
day, the cells were washed three times for 10 min in PBS/Ca/Mg containing 0.2% BSA and then incu-
bated with Alexa Fluor 568–labeled ALO-D4 (a modified cytolysin that binds to ‘accessible choles-
terol’ in the plasma membrane) (Das et al., 2014; Das et al., 2013; Gay et al., 2015) for 2 hr at 4˚C.
Samples were washed three times for 1 min with PBS/Ca/Mg, fixed with 3% PFA in PBS/Ca/Mg, per-
meabilized with 0.2% Triton X-100 in PBS/Ca/Mg, and blocked with PBS/Ca/Mg containing 5% don-
key serum and 0.2% BSA. Cells were then incubated with a goat antibody against mouse LPL (12 mg/
ml) (Page et al., 2006) for 1 hr at room temperature followed by a 30-min incubation with an
Alexa Fluor 647–labeled donkey anti–goat IgG (ThermoFisher Scientific; 1:500). DNA was stained
with DAPI, and coverslips were mounted onto glass slides in ProLong Gold mounting media (Ther-
moFisher Scientific). Images were recorded with a Zeiss LSM700 confocal microscope.
Administration of [13C]fatty acids, [13C]glucose, and [2H]TRLs to mice
C57BL/6 mice with CT-2A gliomas (of three-week duration) were given 80 ml of [13C]fatty acids (~1
mg/ml; Cambridge Isotope Laboratories) or 80 ml of [13C]glucose (3 mg/kg body weight; Cambridge
Isotope Laboratories) by oral gavage every 12 hr for 36 hr (three doses). To study TRL metabolism,
mice were injected intravenously with a single bolus of [2H]TRLs (40 mg triglycerides in 100 ml) via the
tail vein. The [2H]TRLs were isolated from the plasma of Gpihbp1–/– mice after administering deuter-
ated fatty acids by gastric gavage (He et al., 2018a). After allowing the [2H]TRLs to circulate for 1
min or 30 min, the mice were perfused through the heart with 15 ml of ice-cold PBS/Ca/Mg at 3 ml/
min (10 ml though the left ventricle and 5 ml through the right ventricle). Next, the mice were perfu-
sion-fixed through the left ventricle with 10 ml of ice-cold 4% N-(3-dimethylaminopropyl)-N0-ethylcar-
bodiimide hydrochloride (‘carbodiimide;’ Sigma-Aldrich) (mass/vol) and 0.4% glutaraldehyde
(Electron Microscopy Sciences) (vol/vol) in 0.1 M phosphate buffer. The heart, brain, and glioma
tumors were collected and placed in 0.1 M phosphate buffer containing 4% carbodiimide and 2.5%
glutaraldehyde for 2 hr at 4˚C. Tissues were cut into 1-mm3 pieces and fixed overnight in 2.5% glu-
taraldehyde, 3.7% PFA, and 2.1% sucrose in 0.1 M sodium cacodylate (pH 7.4).
Preparation of tissue sections for NanoSIMS imaging and electron
microscopy
After fixation, 1-mm3 pieces of tissue were rinsed three times (10 min each) in 0.1 M sodium cacody-
late buffer (pH 7.4) and fixed with 2% OsO4 (Electron Microscopy Sciences) in 0.1 M sodium cacody-
late on ice for 90 min. The samples were rinsed three times (10 min each) with distilled water and
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stained overnight with 2% uranyl acetate at 4˚C. On the following day, the samples were rinsed three
times for 10 min each with distilled water and then dehydrated with increasing amounts of ethanol
(30%, 50%, 70%, 85%, 95%, and 100%; 3  10 min) before infiltration with Embed812 resin (Electron
Microscopy Sciences) diluted in acetone (33% for 2 hr; 66% overnight; 100% for 3 hr). The samples
were embedded in polyethylene molds (Electron Microscopy Sciences) with fresh resin and polymer-
ized in a vacuum oven at 65˚C for 48 hr. The polymerized blocks were then removed from the molds,
trimmed, and sectioned.
For transmission electron microscopy, 65-nm sections were cut and collected on freshly glow-dis-
charged copper grids (Ted Pella) that were coated with formvar and carbon. Sections were then
stained with Reynold’s lead citrate solution for 10 min. Images were acquired with an FEI T12 trans-
mission electron microscope set to 120 kV accelerating voltage and a Gatan 2K  2K digital camera
(Electron Imaging Center).
For NanoSIMS analyses, 500-nm sections were cut with a Leica UC6 ultramicrotome and collected
on silicon wafers. Sections of tissue were coated with ~5 nm of platinum and analyzed with Nano-
SIMS 50L or NanoSIMS 50 instruments (CAMECA). Samples were scanned with a 16-KeV 133Cs+-
beam, and secondary electrons (SEs) and secondary ions (1H–, 2H–, 12C–, 13C–, 12C14N–) were
collected. A 50  50-mm region of the section was pre-sputtered with a ~1.2-nA beam current (pri-
mary aperture D1 = 1) to reach a dose of ~1  1017 ions/cm2 to remove the platinum coating and
implant 133Cs+ in order to ensure a steady state of secondary ion release. A ~40  40-mm region was
imaged with an ~3-pA beam current (primary aperture D1 = 2) and a dwell time of ~10 ms/pixel per
frame for multiple frames. Both 256  256–pixel and 512  512–pixel images were obtained. Images
were prepared using the OpenMIMS plugin in ImageJ. For image quantification, 2H/1H and 13C/12C
ratios in the regions of interests were calculated with the OpenMIMS plugin and processed by
GraphPad Prism 7.0.
Tumor studies in wild-type and Gpihbp1-deficient mice
Three-month-old C57BL/6 wild-type (five females, six males) and Gpihbp1–/– mice (six females, five
males) were injected intracranially with CT-2A glioma cells stably expressing a Gaussia luciferase
reporter gene (4  105 cells/mouse). Cells were injected 1 mm posterior and 2 mm lateral to the
bregma at a depth of 2 mm. Tumor burden was monitored every three days by measuring Gaussia
luciferase in the blood (Mai et al., 2017; Tannous, 2009). Mice were weighed at weekly intervals
and were euthanized when they lost >20% of their body weight. After the mice were euthanized,
their tumors and brains were weighed. All studies were approved by UCLA’s Animal Research
Committee.
Gaussia luciferase measurements
To measure the levels of secreted Gaussia luciferase (sGluc), blood was obtained from the tail vein
of mice and mixed with 50 mM EDTA to prevent coagulation. 5 ml of blood was transferred to a 96-
well plate, and sGluc activity was measured by chemiluminescence after injecting 100 ml of 100 mM
coelentarazine (Nanolight) (Mai et al., 2017; Tannous, 2009). Data were plotted as relative light
units (RLU).
Quantifying mouse and human transcripts by qRT-PCR
C57BL/6 wild-type mice and Lpl–/–MCK-hLPL mice were anesthetized with isoflurane and perfused
with PBS. Heart, brown adipose tissue (BAT), and quadricep were harvested and flash-frozen in liq-
uid nitrogen. RNA was isolated with TRI reagent (Molecular Research), and quantitative (q)RT-PCR
measurements were performed in triplicate with a 7900HT Fast real-time PCR system (Applied Bio-
systems). Gene expression was calculated with a comparative CT method and normalized to levels
of cyclophilin A expression. Primers for mouse Gpihbp1, mouse Lpl, and human LPL are described in
the ’Key Resources Table’.
VEGF treatment of brain endothelial cells
Mouse brain microvascular endothelial cells (bEnd.3; ATCC #CRL-2299) were plated into 6-well
plates and grown in DMEM media containing 10% FBS, 1% glutamine, and 1% sodium pyruvate
overnight. On the next day, cells were rinsed with PBS and incubated in medium containing
Hu et al. eLife 2019;8:e47178. DOI: https://doi.org/10.7554/eLife.47178 22 of 29
Research article Biochemistry and Chemical Biology Human Biology and Medicine
recombinant mouse VEGF (100 ng/ml; Sigma) for another 24 hr. RNA was isolated with TRI reagent
(Molecular Research), and qRT-PCR measurements were performed in triplicate with a 7900HT Fast
real-time PCR system (Applied Biosystems). Gene expression was calculated with a comparative CT
method and normalized to cyclophilin A expression. Primers for mouse Gpihbp1, Cd31, Angpt2,
Cxcr4, and Dusp5 are described in the ’Key Resources Table’.
Cell lines
CT-2A cells were obtained originally from the Seyfried laboratory and have been extensively tested
and characterized (Seyfried et al., 1992). These cells also robustly expressed GFAP. The bEnd.3
cells were obtained from ATCC with a proper ‘certificate of analysis’. All cell lines were negative for
mycoplasma contamination.
Statistics
Statistical analyses of data were performed with GraphPad Prism 7.0 software. All data are shown as
the means ± standard deviations. Differences were assessed using a Student’s t-test with Welch’s
correction.
Study approval
All tissue samples from patients were obtained after informed consent and with approval from the
UCLA Institutional Review Board (IRB; protocol 10–000655). Animal housing and experimental proto-
cols were approved by UCLA’s Animal Research Committee (ARC; 2004-125-51, 2016–005) and the
Institutional Animal Care and Research Advisory Committee of the KU Leuven (085/2016). The ani-
mals were housed in an AAALAC (Association for Assessment and Accreditation of Laboratory Ani-
mal Care International)-approved facility and cared for according to guidelines established by
UCLA’s Animal Research Committee. The mice were fed a chow diet and housed in a barrier facility
with a 12 hr light-dark cycle.
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